AD109, a once-nightly oral pill, showed clinically meaningful benefits in a Phase 3 trial of 646 adults with obstructive sleep apnea. The medication reduced breathing interruptions by about 44% versus under 20% for placebo; more than 40% of participants moved to a milder OSA category, and roughly 18% achieved full control. Side effects were mostly described as mild, but 21% discontinued treatment. The FDA has granted AD109 Fast Track status as development continues.
Once-Nightly Pill AD109 Shows Promise as an Alternative Treatment for Sleep Apnea
A new oral medication, AD109, produced encouraging results in a Phase 3 clinical trial and may offer an alternative for people with obstructive sleep apnea (OSA) who cannot tolerate or choose not to use continuous positive airway pressure (CPAP) devices.
Phase 3 Trial Results
In a multicenter Phase 3 study of 646 adults with mild to severe OSA, participants took a once-nightly pill of AD109. Investigators reported that more than 40% of participants improved to a less severe OSA category and approximately 18% achieved full control of the condition. The trial measured breathing interruptions (apneas and hypopneas) and found an average reduction of about 44% among those taking AD109, compared with under a 20% reduction in the placebo group.
How AD109 Works
AD109 is designed to support the upper airway by strengthening or stabilizing throat muscles, making the airway less likely to sag or collapse during sleep. This mechanism aims to reduce the repeated blockages that characterize obstructive sleep apnea.
Safety and Tolerability
Side effects in the trial were described as mostly mild and expected. However, 21% of participants discontinued treatment because of adverse effects. Despite this dropout rate, the U.S. Food and Drug Administration (FDA) has granted AD109 Fast Track designation to accelerate its development and review, reflecting a need for new, well-tolerated treatment options for OSA.
Study details and results were summarized by ScienceDaily from materials provided by the American Thoracic Society; the trial was published in the American Journal of Respiratory and Critical Care Medicine.
Context and Next Steps
Obstructive sleep apnea affects an estimated nearly 1 billion adults worldwide and about 30 million people in the United States. It is associated with increased risks of cardiovascular disease, stroke, daytime sleepiness, and other health problems. CPAP remains the most common treatment for diagnosed patients, but many cannot tolerate it or decline to use it. AD109 may become a useful option for those patients if further review confirms benefits and acceptable tolerability. Additional regulatory review and possible follow-up studies will determine whether AD109 becomes widely available.
Help us improve.
